NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Zhengye Biotechnology Holding Limited (ZYBT) Stock Analysis

Zhengye Biotechnology Holding Limited (ZYBT) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ZYBT

$1.46

−$0.03 (−2.01%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZYBT with… →

ZYBT Key Statistics

As of Oct 21, 2026

Trading

Open: $1.49
Previous Close: $1.49
Day's Range: 1.45–1.53
52-Week Range: 0.62–8.01
Volume: 50.18K

Valuation

Market Cap: $69.19M
P/E Ratio: unprofitable
P/S ratio: 0.59
EPS (ttm): −0.20

Financials (FY)

Revenue (FY): $116.36M−37.56%
Net Income (FY): −$69.78M−716.96%
Profit margin: −59.97%
Shares Outstanding: 47.39M
1-Year Return: −41.83%

Dividend and dates

Avg Volume: 2.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ZYBT closed at $1.46, −41.83% over 1 year.

Zhengye Biotechnology Holding Limited (ZYBT) has a market capitalization of $69.19M.

In fiscal 2025, ZYBT reported revenue of $116.36M.

ZYBT Stock Return by Calendar Year

Zhengye Biotechnology Holding Limited (ZYBT) return since Jan 2025: what $10,000 became

1 year: $10,000 $5,817; −41.83%
Since Jan 2025: $10,000 $3,004; −69.96%

If you had invested $10,000 in Zhengye Biotechnology Holding Limited (ZYBT) at the close on January 7, 2025, the earliest close on record here, it would have been worth $3,004 at the close on October 21, 2026: −69.96% in total, −49.02% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+26.96%
2025	−76.34%

As of October 21, 2026.

ZYBT Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$116.36M	−$69.78M	−60.0%
2024	$186.36M	$11.31M	6.1%
2023	$211.65M	$31.46M	14.9%
2022	$260.27M	$46.74M	18.0%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$116.36M	$23.87M	−$68.25M	−$69.78M	−60.0%
2024	$186.36M	$91.30M	$17.17M	$11.31M	6.1%
2023	$211.65M	$117.51M	$47.64M	$31.46M	14.9%
2022	$260.27M	$147.88M	$66.09M	$46.74M	18.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZYBT Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks

Metric	ZYBT	Drug Manufacturers - Specialty & Generic median	vs median
P/S ratio	0.59	2.10	0.3x the median
Profit margin	−59.97%	−8.14%	51.8 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Zhengye Biotechnology Holding Limited (ZYBT) is capitalised at $69.19M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 269 employees.

ZYBT last closed at $1.46 on October 21, 2026. That is −$0.03 (−2.01%) against the previous close. The 52-week range on file runs from $0.62 to $8.01. The latest close sits 137.01% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $116.36M. Against the prior fiscal year total of $186.36M, that is a change of −37.56%. The same year closed with a net loss of $69.78M. The reported profit margin is −59.97%. That is 51.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.2.

Across the 4 fiscal years on file, revenue moves from $260.27M in 2022 to $116.36M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.59. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 1,063.95%. Over the trailing twelve months the total return is −41.83%. The stored price history starts on January 7, 2025, and the total return since then is −69.96%.

Growth & Income

The record shows no dividend for ZYBT.

The record holds one complete calendar year, 2025, which returned −76.34%. So far in 2026 the total return is +26.96%.

Peer Comparison

Zhengye Biotechnology Holding Limited (ZYBT) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Zhengye Biotechnology Holding Limited	ZYBT	$69.19M	—
Takeda Pharmaceutical Company Limited	TAK	$63.67B	—
Teva Pharmaceutical Industries Limited	TEVA	$47.37B	67.7
Haleon plc	HLN	$44.06B	20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Zhengye Biotechnology Holding Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

TEVA

Teva Pharmaceutical Industries Limited

$47.37B

HLN

Haleon plc

$44.06B

ZTS

Zoetis Inc.

$32.90B

UTHR

United Therapeutics Corporation

$24.17B

VTRS

Viatris Inc.

$21.19B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Visit website →